CymaBay Therapeutics, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Restructuring (benefit) charges
Total operating expenses

Loss from operations
Other income (expense), net:
Interest income
Interest expense
Other income
Total other income (expense), net
Net loss
Other comprehensive (loss) income:
Unrealized gain (loss) on marketable securities, net of tax
Total other comprehensive income (loss)
Comprehensive loss
Basic net loss per common share
Diluted net loss per common share
Weighted average common shares outstanding used to calculate basic net loss per common share
Weighted average common shares outstanding used to calculate diluted net loss per common share

Comments